BIMZELX® (bimekizumab-bkzx) Data in Hidradenitis Suppurativa Showed Improvements in Pain and Resolution of Draining Tunnels Sustained to Three Years

UCB, a global biopharmaceutical company, today announced three-year data from the BE HEARD trials for BIMZELX® (bimekizumab-bkzx) in moderate-to-severe hidradenitis suppurativa (HS). BIMZELX, the ...

Spyre Therapeutics to Participate in Upcoming November Investor Conferences

Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel ...
PharmiWeb

TREMFYA® (guselkumab) receives European Commission approval for subcutaneous induction through to maintenance in adults with ulcerative colitis, now the first IL-23 inhibitor ...

Guselkumab offers the flexibility of self-administration from the start of treatment in both ulcerative colitis (UC) and Crohn’s disease (CD),1,2,3 providing the simplicity of a fully subcutaneous ...
The Kit

Scary-Easy Halloween Manicures You Can (Mostly) Do Yourself

Need a last minute costume idea? Canadian nail artists share their tricks for getting spooky-chic Halloween nails.
Investor's Business Daily on MSN

Coal Stocks Pare Gains Amid The Rare Earths Craze

Stocks for some coal companies are up 200% this year, as investors hope they'll reinvent themselves as rare earth miners.
BMJ Open

Quality assessment of irritable bowel syndrome-related medical information on major video platforms in China: a cross-sectional study

Objective In China, a large number of health-related short videos are posted on video platforms, including educational videos ...